Seeking Alpha

smucelli

smucelli
Send Message
View as an RSS Feed
View smucelli's Comments BY TICKER:
Latest  |  Highest rated
  • 6 Reasons Aradigm Corporation Is An Excellent Risk Vs. Reward Opportunity [View article]
    Thank you very much for writing this great article! I had worked for Aradigm from the inhaled insulin days with Novo, 2003-2008. I am very happy to see they have survived (with new management and drugs), and are ready to bloom into a very successful company. I bought my shares in late 2012 and have been holding tight and waiting since, because I knew they are very very good!!!
    Aug 8 01:00 PM | 1 Like Like |Link to Comment
  • The Stock Market Has Reached "A Permanently High Plateau" -- If The Fed Does Not Mess Up Again [View article]
    Taxes only permanent to the 99%, death however is 100%.
    Jul 24 01:35 PM | 1 Like Like |Link to Comment
  • Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) [View article]
    Under the radar stock. A Show me stock, which is too bad because this antibiotic drug will be a huge success.
    Jun 23 11:02 AM | Likes Like |Link to Comment
  • Acadia Pharmaceuticals: 4 Different Insiders Have Sold Shares This Month [View article]
    I disagree. I see $15 in your future.
    Apr 20 10:27 AM | 1 Like Like |Link to Comment
  • MannKind resumes trading; shares +131.6% AH [View news story]
    VERY NICE!
    Apr 1 06:28 PM | 3 Likes Like |Link to Comment
  • MannKind And Afrezza's NDA Evaluation: What Is The Real Justification For The Advisory Committee? [View article]
    Awesome article but long. Above is correct, I could not read all.
    I am pulling for MNKD! I am current long Aradigm ARDM (who did liquid inhaled insulin but halted phase 3 trials in 2008). The more options the better for patients, and alternating between options is good too!
    Mar 27 11:55 PM | 3 Likes Like |Link to Comment
  • Aradigm Announces Changes to Its Board of Directors [View article]
    We know ARDM will pop sooner or later, this hidden gem!
    Sep 18 11:42 AM | Likes Like |Link to Comment
  • MannKind Stock: High Risk, High Reward [View article]
    High risk, high reward, not low risk.
    Aug 30 01:21 PM | 2 Likes Like |Link to Comment
  • MannKind Stock: High Risk, High Reward [View article]
    Thank you so much for mentioning Aradigm (ARDM) and Novo Nordisk in this article. Aradigm is such an over-looked upcoming company. Aradigm still recovering from Novo Nordisk dropping the inhaled insulin program, killing ARDM pps. However ARDM now has a new partner Grifols and almost ready to start Ph3. You go MNKD. I think you can make it! And you go ARDM!
    Aug 29 06:38 PM | Likes Like |Link to Comment
  • Grifols buys a 35% stake in Aradigm to get drug rights to Ciproflaxin [View news story]
    Big Deal....no stock price movement.
    Aug 28 02:53 PM | Likes Like |Link to Comment
  • Patience Required For Dara Bio Investment [View article]
    DARA darling is a very tough sell for me.

    Better picks out there if you work at it, instead of re-hashing the old.
    Aug 20 05:17 PM | 1 Like Like |Link to Comment
  • Grifols (GRFS -1.6%) says that Aradigm (ARDM.OB) has received shareholder approval for its license agreement giving GRFS access to Aradigm's proprietary formulations of inhaled ciprofloxacin, which is used for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis. In conjunction with the licensing agreement, GRFS will acquire 35% of Aradigm's common stock at a price per share of $0.124 for a total investment of approximately $26M. [View news story]
    Great post about Aradigm / Grifols by rehdvm2004

    The "deal" had to be approved by stockholders. Now the way is clear to have a preclinical sit down with FDA and/or EMEA and get the Phase III study started. INSM achieve only one log bacteria reduction with 28 days of treatment and 28 days rest. That was with a once per day Rx regimen. Pulmoquin is also once per day, but the Phase IIb study showed FOUR logs reduction of bacteria. One log is a count of 10 bacteria. So Pulmoquin was showing a 10,000 fold reduction in the marker bacteria. Grifols made a great choice. It keeps ARDM funded for the Phase III and points to the future for the drug. There will be other studies that come up along the way and I am sure that the CF/Pa market is just a matter of cross-filing the Phase III data from the current study. The regulatory agencies have had so many new inhalational antibiotics of late, that the protocols, diagnostic tests and comparative aspects of clinical data analysis are all algorithms.

    ARDM is not known yet, but give it 6 to 18 months!
    Jul 16 03:06 PM | Likes Like |Link to Comment
  • Aradigm Shareholders Approve Collaboration Transaction With Grifols, S.A. to Develop and Commercialize Pulmaquin [View article]
    Great post about Aradigm / Grifols by rehdvm2004

    The "deal" had to be approved by stockholders. Now the way is clear to have a preclinical sit down with FDA and/or EMEA and get the Phase III study started. INSM achieve only one log bacteria reduction with 28 days of treatment and 28 days rest. That was with a once per day Rx regimen. Pulmoquin is also once per day, but the Phase IIb study showed FOUR logs reduction of bacteria. One log is a count of 10 bacteria. So Pulmoquin was showing a 10,000 fold reduction in the marker bacteria. Grifols made a great choice. It keeps ARDM funded for the Phase III and points to the future for the drug. There will be other studies that come up along the way and I am sure that the CF/Pa market is just a matter of cross-filing the Phase III data from the current study. The regulatory agencies have had so many new inhalational antibiotics of late, that the protocols, diagnostic tests and comparative aspects of clinical data analysis are all algorithms.

    Thank you rehdvm2004!

    ARDM is not known yet, but give it 6 to 18 months!
    Jul 16 03:02 PM | Likes Like |Link to Comment
  • Uni-Pixel: A Picture Is Worth A Thousand Words [View article]
    I have no positions here, thank you!

    From SA: Seth Shaw is the pseudonym of an investor in individual stocks. He is a proponent in only investing in ideas which he can evaluate himself.

    Really...better evaluate a good lawyer!

    Seth says: "Just in case this isn't convincing enough, we'll be back in a few weeks with an expose on the shady characters all around the company - in the management team, the board, and among the owners".

    Can't wait Seth!!!

    Keep digging a deeper hole for yourself.
    May 31 07:27 PM | 4 Likes Like |Link to Comment
  • The FDA Vs. AVEO's Tivozanib: Who Does The Dying? [View article]
    Great article!

    What a bunch of BS coming from FDA & Pazdur today:

    FDA oncology chief Pazdur vows to accelerate "breakthrough" drug R&D

    May 31, 2013 | By John Carroll

    CHICAGO -- The FDA's oncology chief, Richard Pazdur, used his turn in front of the press mob at ASCO today to make some very public vows about his commitment to the newly launched breakthrough-drug program, that intriguing new classification for certain stellar therapeutic programs that will be extended VIP status at the agency.

    Pazdur stressed that any drug development team working on a breakthrough drug will have no trouble getting steady feedback from the agency, and in particular the oncology division he runs. Pazdur and the agency view these drugs as potentially "transformative" therapies capable of changing the course of patients' lives. And the agency is committed to spend time in an "iterative fashion," holding monthly meetings and teleconferences to advise teams on accelerating the whole development process, with a goal of quickening final marketing decisions.

    This is going to be a "different communication structure," Pazdur promises, "with much more of a continuous dialogue with sponsors." Together, regulators and development teams can change endpoints, downsize trial sizes in light of the data they're seeing and expedite reviews--adaptive research with regulatory input.

    ALMOST FUNNY IF NOT PATHETIC.
    May 31 06:18 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
28 Comments
19 Likes